As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include interesting publications on pediatric CML and from LMICs.

Read Professor Hughes' CML publications of the month: December 2025

Clinical CML papers

• How can we chop CML with an ASXL1?
  Cortes J. Blood, December 2025 – open access publication
  (Commentary on the article highlighted in September 2025: Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Shanmuganathan N. et al Blood 2025 doi: https://doi.org/10.1182/blood.2025030259)
• Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial
  Cortes JE et al. Blood, December 2025
• Is there a best frontline therapy in chronic myeloid leukemia?
  Jain AG et al. Haematologica, December 2025 (epub ahead of print) – open access publication
  
• Treatment expectations and goals among patients with chronic myeloid leukemia in Germany: a patient-centred perspective
  Ernst P et al. Leukemia, December 2025 (epub ahead of print) – open access publication
  
• The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-a2b in newly diagnosed chronic phase chronic myeloid leukemia
  Yeung DT et al. Br J Haematol, December 2025 (epub ahead of print)
• How I treat advanced phases of CML?
  Mauro MJ. Blood, December 2025 (epub ahead of print)
• Improving quality of life for patients with chronic myeloid leukemia through supportive care, low-dose therapy, switching, and treatment-free remission
  Flynn KE & Atallah E. Haematologica, December 2025 (epub ahead of print) – open access publication
  
• Prognostic factors in chronic myeloid leukemia at diagnosis and for treatment-free remission
  Rea D. Haematologica, December 2025 (epub ahead of print) – open access publication
• Treatment of chronic myeloid leukemia chronic phase in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
  Vandenberghe P et al. Hematology, December 2025 – open access publication
• Second-line use of dasatinib and nilotinib in a real-world patient population with chronic phase chronic myeloid leukemia
  Toptas T et al. Hematology, December 2025 – open access publication
  
• Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia
  Cheng F & Li W et al. Haematologica, December 2025 (epub ahead of print) – open access publication
• Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia
  Suzuki K et al. Int J Hematol, December 2025 (epub ahead of print)
• Empirical and projected economic burden of chronic myeloid leukemia in Sweden from 2015 – 2030: A population-based study
  Chen EY et al. Br J Haematol, December 2025 (epub ahead of print) – open access publication
  
• Sequential occurrence of BCR::ABL1-negative MPN and CML and vice versa: results from a real-world cohort
  Schweneker K et al. Int J Hematol, December 2025 (epub ahead of print) – open access publication

Scientific CML papers

• Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients
  Cayssials E et al. Cancer Immunol Immunother, December 2025 – open access publication
• Stroma-driven horizontal transfer of TCA-related proteins mediates metabolic plasticity and imatinib resistance in chronic myeloid leukemia
  Chroscicki P et al. Cell Commun Signal, December 2025 (epub ahead of print) – open access publication
• Immune surveillance in chronic myeloid leukemia: Tumor antigen expression and CD8(+) T cell function in the context pf treatment-free remission
  Kvásnik P et al. Arch Immunol Therp Exp (Warsz), December 2025 – open access publication
  
• Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy
  Arif K et al. BMC Cancer, December 2025 (epub ahead of print) – open access publication
  
• An overview of strategies and challenges adopted to silence BCR::ABL gene by small interfering RNA
  Fancello L et al. Nanomedicine (Lond), December 2025
• P38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia
  Bhat M et al. Exp Cell Res, December 2025 (epub ahead of print)

Pediatric CML papers

• Real-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG(Plus)-CML 2023
  Fan Z et al. Cancer, December 2025 – open access publication

LMIC papers

• Insights into treatment-free remission (TFR) outcomes in chronic myeloid leukemia (CML) – a tertiary centre experience in Malaysia
  Liam CCK et al. Blood Res, December 2025– open access publication
  
• Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil
  Pagnano K. et al. Blood Global Hematology December 2025
• The needs of the many outweigh the needs of the few 
  Lipton JH., Blood Global Hematology December 2025 
  (Commentary on the article: Clinical outcomes of patients with chronic myeloid leukemia with asciminib provided by a compassionate program in Brazil. Pagnano K. et al. Blood Global Hematology December 2025 doi: https://doi.org/10.1016/j.bglo.2025.100035)